D. Petrylak

发表

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

S. Culine, J. Hainsworth, R. Huddart, 2017, The Lancet.

The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

G. Haas, A. Villers, A. Armstrong, 2022, The Prostate.

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib

D. Petrylak, S. Watkins, A. Loehr, 2022, Frontiers in Oncology.

M. Galsky, E. Heath, A. Balar, 2022, European Urology.

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

G. Pond, P. Albers, T. Choueiri, 2013, European urology.

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

M. Burotto, A. Armstrong, L. Lacombe, 2022, Journal for ImmunoTherapy of Cancer.

Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984

M. Loda, E. V. Van Allen, P. Glazer, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary results from TRITON2: A phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations.

H. Scher, A. Bryce, A. Patnaik, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer

M. Milowsky, S. Srinivas, J. Rosenberg, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma

S. Culine, M. Climent, T. Choueiri, 2017, The New England journal of medicine.

An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer

A. Ravaud, T. Powles, J. Carles, 2021, Nature Medicine.

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Thierry Gil, Camilla Thellenberg Karlsson, I. Tannock, 2013, The Lancet. Oncology.

The utility of prostate‐specific antigen in the management of advanced prostate cancer

E. Crawford, G. Andriole, M. Garnick, 2013, BJU international.

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

T. Powles, H. Nishiyama, C. Sternberg, 2022, Nature Communications.

697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

T. Powles, M. Galsky, A. Gupta, 2020 .

An open‐label, single‐arm, phase 2 trial of the polo‐like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer

G. Sonpavde, M. Ernstoff, M. Carducci, 2014, Cancer.

Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

David C. Smith, M. Kohli, D. Petrylak, 2014, Cancer.

Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up.

T. Powles, E. Plimack, A. Balar, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer

M. Morris, A. Armstrong, C. Higano, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

C. Higano, K. Kern, L. Appleman, 2023, Journal for ImmunoTherapy of Cancer.

The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.

G. Haas, A. Villers, B. Alekseev, 2023, European urology.

Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.

T. Powles, S. Park, C. Sternberg, 2023, European urology.

Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD

C. Drake, D. Shaffer, A. Saci, 2019, Annals of Oncology.

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

T. Powles, C. Sternberg, D. Petrylak, 2022, British journal of clinical pharmacology.

Japanese subgroup analysis of EV‐301: An open‐label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma

T. Powles, J. Rosenberg, T. Kojima, 2022, Cancer medicine.

Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients

I. Kang, J. Vinetz, M. Simonov, 2022, Cancer Investigation.

Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic.

I. Thompson, C. Tangen, D. Dizon, 2023, JCO oncology practice.

Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T

P. Kantoff, C. Higano, E. Small, 2014, Prostate Cancer and Prostatic Disease.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

S. Culine, M. Climent, T. Choueiri, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial.

William Berry, Oliver Sartor, J Alfred Witjes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

M. Milowsky, S. Srinivas, J. Rosenberg, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

S. Culine, M. Climent, T. Choueiri, 2019, Annals of Oncology.

747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE-052

J. Lunceford, T. Powles, M. Climent, 2020 .

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Anthony Patterson, Mark K Buyyounouski, Khurshid A Guru, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

E. Crawford, C. Higano, D. Petrylak, 2015, The Journal of urology.

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility

E. Crawford, C. Higano, D. Petrylak, 2017, Therapeutic advances in medical oncology.

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma.

T. Powles, G. Sonpavde, Y. Loriot, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.

David C. Smith, J. Lang, E. Heath, 2017 .

The utility of prostate‐specific antigen in the management of advanced prostate cancer

E. Crawford, G. Andriole, M. Garnick, 2013, BJU international.

A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors

T. Yap, J. Bono, G. Blumenschein, 2007 .

PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study

David C. Smith, B. Somer, N. Stambler, 2019, The Prostate.

Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR/HDAC targeted therapy

Viswanathan Muthusamy, K. Anderson, D. Petrylak, 2023, NPJ precision oncology.

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

M. Cooperberg, H. Beltran, H. Scher, 2024, JU open plus.

Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study.

G. Kramer, S. Byun, M. D. De Santis, 2023, Journal of Clinical Oncology.

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.

F. Saad, A. Armstrong, D. Shaffer, 2021, European journal of cancer.

Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.

N. Agarwal, C. Kyriakopoulos, C. Sternberg, 2023, Journal of Clinical Oncology.

Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy.

N. Agarwal, C. Sternberg, P. Grivas, 2023, Journal of Clinical Oncology.

Primary analysis of TROPHY-U-01 cohort 2, a phase 2 study of sacituzumab govitecan (SG) in platinum (PT)-ineligible patients (pts) with metastatic urothelial cancer (mUC) that progressed after prior checkpoint inhibitor (CPI) therapy.

N. Agarwal, C. Sternberg, A. Balar, 2023, Journal of Clinical Oncology.

Becker Digital

M. Burotto, G. Gravis, J. Pérez-Gracia, 2022 .

Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.

T. Powles, J. Bellmunt, N. Tsuchiya, 2023, European urology.

Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3

P. Grivas, Y. Loriot, S. Tagawa, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

J. Rosenberg, D. Petrylak, A. Necchi, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

M. Cooperberg, H. Beltran, H. Scher, 2024, JU open plus.

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

T. Flaig, S. Bracarda, A. Carret, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

H. Scher, A. Bryce, W. Abida, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

The Impact of Late LHRH Agonist Dosing on Testosterone Suppression in Prostate Cancer Patients: An Analysis of US Clinical Data.

J. Moul, C. Higano, D. Petrylak, 2020, The Journal of urology.

Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.

H. Beltran, M. Taplin, J. Calais, 2024, Cancer.

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .